ArticleCJC open2025
Adverse Drug Events Associated with Optimizing Heart Failure Pharmacotherapy in Older Adults with Frailty: A Qualitative Study.
Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adverse drug events (ADEs) from heart failure (HF) pharmacotherapy are common in older people with frailty, but evidence as to how to optimize HF pharmacotherapy is unclear. This qualitative study explores consumer and healthcare professional (HCP) perspectives on ADEs and adverse drug withdrawal effects (ADWEs) related to HF pharmacotherapy to inform key domains of a conceptual model. Methods: A purposive and snowball sample of participants were contacted directly or recruited across Australia and New Zealand to participate in qualitative semistructured interviews and focus groups. Frailty was explained as a measure of cumulative deficits and consumers (caregivers or individuals aged ≥ 65 years with HF and frailty) and HCPs caring for older patients with HF and frailty were invited according to their self-perception or evaluation of frailty. General inductive analysis identified themes and a hypothesis-generating conceptual model. Results: Thirty-two participants were recruited (consumers [n = 4), cardiologists and other physicians [n = 9], nurses [n = 8], and pharmacists [n = 11]). Three main themes and 8 subthemes related to individual factors, medications, and access to healthcare services were identified. Consumers stated that they want support to maintain their quality of life but have complex medical issues. Most HCP participants perceived the benefits of HF pharmacotherapy to outweigh the risks of ADEs and are hesitant to deprescribe. Participants wanted improved coordination of multidisciplinary teams and patient access to healthcare services. Conclusions: Perspectives unique to HF pharmacotherapy in older people with frailty characterize how the interplay of HF treatment, ADEs, and ADWEs contributes to individuals' well-being. Future research is needed to further develop the conceptual model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.